Skip to content
OpenCapital
Get started

ResMed RMD Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

LivaNova logo
LivaNovaLIVN
$10.31M-10.2%
Pulmonx Corporation logo
Pulmonx CorporationLUNG
$100K0.0%
Medtronic logo
MedtronicMDT
——
Baxter International logo
Baxter InternationalBAX
——

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$28.27B-19.1%
Enterprise value$27.71B-19.8%
P/E18.6×-6.3×
P/S5.1×-1.7×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's allowance for doubtful accounts receivable (current)?
ResMed (RMD) reported allowance for doubtful accounts receivable (current) of $29.47M in Q1 2026.
How has ResMed's allowance for doubtful accounts receivable (current) changed year-over-year?
ResMed's allowance for doubtful accounts receivable (current) increased by 48.7% year-over-year, from $19.83M to $29.47M.
What is the long-term trend for ResMed's allowance for doubtful accounts receivable (current)?
Over 4 years (2021 to 2025), ResMed's allowance for doubtful accounts receivable (current) has grown at a -8.6% compound annual growth rate (CAGR), from $32.14M to $22.42M.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.